Related Experiment Video
Updated: Sep 14, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
DTX3L E3 ligase: Molecular functions, regulatory mechanisms, and potential as a novel cancer biomarker and
Jiang Liangqian1, Mu Haiyu2, Xing Huixia3
1Department of Laboratory Medicine, Linyi Peoples' Hospital, Linyi, Shandong, China.
Abstract:
The ubiquitin-proteasome pathway is a critical regulatory system in eukaryotic cells, which mediates dynamic and reversible protein modifications through the E1-E2-E3 ubiquitination cascade. E3 ubiquitin ligases, which catalyze substrate-specific ubiquitination for proteasomal degradation, play essential roles in maintaining cellular homeostasis. The deltex E3 ubiquitin ligase 3 L (DTX3L) modulates a variety of biological processes, such as proliferation, cell cycle, migration, invasion and apoptosis. Emerging evidence implicates DTX3L dysregulation in the pathogenesis of multiple malignancies, including cervical cancer, melanoma, prostate cancer, triple-negative breast cancer, glioma and pancreatic cancer. This review synthesizes current knowledge on DTX3L's molecular mechanisms across tumor types, highlighting its role in modulating the stability of oncogenic and tumor-suppressive substrates. As DTX3L emerges as a promising oncology therapeutic target, its molecular functions and regulatory mechanisms offers novel opportunities for rational antitumor drug design. However, the clinical translatability of DTX3L-targeted strategies requires further validation. In conclusion, DTX3L has the potential to serve as a novel cancer biomarker and therapeutic target.
Insights
Deltex E3 ubiquitin ligase 3 L (DTX3L) is crucial for cellular homeostasis and implicated in various cancers. DTX3L
Area of Science:
- Molecular Biology
- Cellular Biology
- Oncology
Background:
- The ubiquitin-proteasome pathway regulates protein stability via ubiquitination.
- E3 ubiquitin ligases, like DTX3L, are key in substrate-specific degradation.
- DTX3L dysregulation is linked to multiple cancer types.
Purpose of the Study:
- To review the molecular mechanisms of DTX3L in cancer.
- To highlight DTX3L's role in modulating oncogenic and tumor-suppressive substrates.
- To explore DTX3L as a potential therapeutic target in oncology.
Main Methods:
- Literature review of studies on DTX3L.
- Synthesis of current knowledge on DTX3L's functions.
- Analysis of DTX3L's role in various malignancies.
Main Results:
- DTX3L modulates proliferation, cell cycle, migration, invasion, and apoptosis.
- DTX3L influences the stability of key cancer-related proteins.
- DTX3L is implicated in cervical cancer, melanoma, prostate cancer, and others.
Conclusions:
- DTX3L is a promising therapeutic target and biomarker for cancer.
- Understanding DTX3L mechanisms offers opportunities for novel drug design.
- Further validation is needed for clinical translation of DTX3L-targeted therapies.
More Related Videos
10:12Author Spotlight: Quantitative Detection of DNA Protein Crosslinks and Their Post-Translational Modifications
Published on: April 21, 2023
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Targeted Cancer Therapies
There are several types of targeted therapies against...
lncRNA - Long Non-coding RNAs
Mitogens and the Cell Cycle
Regulation of Angiogenesis and Blood Supply